Skip to main content

Table 3 Characteristics of PsA patients by depressive symptoms

From: Depressive symptoms are associated with fatigue, poorer functional status and less engagement in sports in axSpA and PsA: an analysis from the RABBIT-SpA cohort

Parameter

No or mild depressive symptoms

N = 868

Moderate depressive symptoms

N = 256

Severe depressive symptoms

N = 101

Total

N = 1225

Age, years, mean (SD)

52.3 ± 12.8

51.3 ± 10.9

52.8 ± 11.1

52.1 ± 12.3

Sex, female, n (%)

489 (56)

158 (62)

72 (71)

719 (59)

Disease duration, years, mean (SD)

6 ± 7.1

6.7 ± 8.3

7.8 ± 8.1

6.3 ± 7.4

School, ≥ 10 years, n (%)

680 (80)

192 (76)

75 (75)

947 (79)

Currently employed, n (%)

555 (67)

155 (65)

52 (54)

762 (66)

Current smoking, n (%)

230 (28)

82 (33)

37 (37)

349 (30)

Engaging in sports, ≥ 1 h/week, n (%)

386 (46)

87 (35)

29 (29)

502 (42)

Obesity (BMI ≥ 30), n (%)

304 (36)

98 (39)

56 (55)

458 (38)

Comorbidities, 3 or more, n (%)

247 (29)

89 (35)

46 (46)

382 (31)

Depression as known comorbidity, n (%)

64 (7)

60 (23)

25 (25)

149 (12)

Of those, depression treated, n (%)

44 (69)

39 (65)

19 (76)

102 (68)

Fibromyalgia as comorbidity, n (%)

30 (4)

21 (8)

11 (11)

62 (5)

Naive to biologic therapy, n (%)

442 (60)

107 (50)

45 (50)

594 (57)

Systemic glucocorticoids, n (%)

255 (30)

92 (36)

46 (46)

393 (32)

Non-opioid analgesics, n (%)

92 (12)

36 (16)

33 (34)

161 (15)

Opioids, n (%)

31 (4)

21 (9)

15 (16)

67 (6)

CRP ≥ 5 mg/l, n (%)

314 (41)

104 (44)

41 (45)

459 (42)

Tender joint count (0–68), mean (SD)

6.4 ± 7.7

7.2 ± 7.2

11.1 ± 10.7

6.9 ± 8.0

Swollen joint count (0–66), mean (SD)

3.0 ± 4.1

3.5 ± 4.7

4.7 ± 6.2

3.3 ± 4.4

Enthesitis, number of sites (0–16), mean (SD)

2.9 ± 2.5

3.6 ± 2.1

3.8 ± 3.2

3.2 ± 2.5

Nail psoriasis, n (%)

344 (40)

103 (40)

50 (50)

497 (41)

Body surface area, mean (SD)

8.3 ± 14.6

8.9 ± 16.2

10.2 ± 17.9

8.6 ± 15.2

DAPSA, mean (SD)

20.6 ± 12.5

24.8 ± 12.7

32.6 ± 15.9

22.5 ± 13.3

Physician global disease activity, NRS 0–10, mean (SD)

4.9 ± 1.8

5.5 ± 1.8

6.3 ± 1.6

5.1 ± 1.9

Patient global disease activity, NRS 0–10, mean (SD)

5.2 ± 2.3

6.6 ± 2.1

8 ± 2

5.7 ± 2.4

Patient: DLQI, mean (SD)

4.9 ± 5.5

7.2 ± 6.9

9.2 ± 8.2

5.8 ± 6.2

Patient: HAQ, mean (SD)

0.8 ± 0.6

1.2 ± 0.6

1.6 ± 0.6

0.9 ± 0.7

Patient: Fatigue, NRS 0–10, mean (SD)

4.4 ± 2.2

6.8 ± 2.0

8.1 ± 1.7

5.2 ± 2.7

Patient: Pain, NRS 0–10, mean (SD)

5 ± 2.3

6.4 ± 2.1

7.8 ± 1.7

5.5 ± 2.4

Patient: Sleep disturbance, NRS 0–10, mean (SD)

4.2 ± 2.9

6.3 ± 2.7

7.2 ± 2.7

4.9 ± 3.1

Patient: Current work ability, NRS 0–10 (higher is better), mean (SD)

5.6 ± 2.8

3.7 ± 2.7

3.5 ± 2.9

5 ± 2.9

  1. CRP C-reactive protein, DAPSA Disease Activity in Psoriatic Arthritis, DLQI Dermatology Life Quality Index, HAQ Health Assessment Questionnaire, NRS Numerical rating scale